Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Suneetha Achanti

Suneetha Achanti

Department of Pharmaceutical Analysis, Hindu College of Pharmacy, India

Title: PDAS–MSD- LC MS- Prescriptive Drug Analysis Study in Rat Plasma for Multiple Sclerosis Disease by LC-ESI/MS

Biography

Biography: Suneetha Achanti

Abstract

Prescribing a single drug and its administration is not sufficient in neuro diseases like multiple sclerosis. Combination therapy is growing enormously to decrease the number of medications for a single disease or their associated diseases. In clinical research estimation of concomitant drugs plays a key role to study the drug-drug interactions. The research in the current article has undertaken to provide an accurate method for evaluate the pharmacokinetic parameters of Carbamazepine (CBZ), Duloxetine (DLX), Tamsulosin (TSL) and Teriflunomide (TFM) using Doxofylline (DXF) and Ibuprofen (IBP) as internal standards (IS) in rat plasma by LC- MS when used as combination therapy. The developed bioanalytical method has been validated according to ICH guidelines. The obtained LODs and LOQs of all the drugs were adequate and may useful to perform the pharmacokinetic study in rat plasma. Based on the results, we can conclude that the present method is suitable for quantification of multiple analytes simultaneously without any interference and matrix effects. The concomitant drug analysis along with the target analyte is more advantageous than single compound analysis and also useful in drug interaction and toxicology studies. This method can also be useful in estimating the plasma samples of patients who administer these drugs.